Company news

Annovis Bio, Inc. news in 2026

Annovis Bio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Annovis Announces Pricing of $21.0 Million Public Offering

November 5, 2026

Annovis Announces Launch of Proposed Public Offering

November 4, 2026

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

October 30, 2026

Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

October 29, 2026

Annovis to Attend the CTAD 2026 with Three Presentations

October 22, 2026

Annovis Bio Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's disease

September 24, 2026

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

September 23, 2026

Annovis to Host Corporate Update Webinar on September 2, 2026

August 25, 2026

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

August 14, 2026

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

July 7, 2026

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

July 1, 2026

Annovis Bio Regains NYSE Listing Compliance

May 26, 2026

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

May 20, 2026

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

May 19, 2026

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

May 15, 2026

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

May 7, 2026

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

April 28, 2026

Annovis Closes $10 Million Offering, Extending Cash Runway through Phase 3 Alzheimer's Disease 6-Month NDA Submission

April 13, 2026

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

April 10, 2026

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

April 9, 2026

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

April 2, 2026

Annovis Publishes Historical Review of Buntanetap in The Scientist

March 31, 2026

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

March 19, 2026

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

March 16, 2026

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

March 3, 2026

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

February 12, 2026

Decks in 2026